42 Therapeutics companies

We create and invest in healthcare and technology companies that impact lives all over the world.

A leading European Venture Capital firm investing in early- and growth-stage Life Science companies.

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund.

Novartis Venture Fund is a venture capital firm focused on companies that develop novel therapeutics and platforms.

We invest in cancer innovation, together.

Accelerating the future of minimally invasive care.

We are a life science venture capital investor, delivering knowledge, network, and capital to companies.

Equity investments in early stage biopharma companies with a clear vision and solid scientific evidence.

Aditum Bio is a new model of biotech venture capital, uniquely positioned to rapidly translate scientific discoveries into innovative new medicines.

A £250m specialist venture capital fund that invests in, and creates, new biotech companies to deliver high impact therapeutics for age-related dementias.

Nurturing great biomed companies with Asia focus.

We fund healthy lifespan extension.

Investing in the future of medicine.

We're biomedical researchers investing in a new generation of translational founders.

Pfizer Ventures invests in areas of current or future strategic interest to Pfizer with the goal of remaining at the forefront of life science advances. We iden…

We invest in entrepreneurs targeting platforms that influence large or underserved diseases, technologies that accelerate and expand scientific discovery, and s…

By partnering with organizations at the forefront of transforming the healthcare industry, we seek to identify the companies best positioned to improve the deli…

Invested in breaking ‍through paralysis.

Since 2004, Amgen Ventures has invested in emerging companies to help discover promising medicines and technologies that will bring "Value Healthcare" to patien…

Investing in disruptive, early-stage biopharma companies across Europe.